Pharmaxis Selects Medidata Solutions to Increase Efficiency of Clinical Data Management and Reporting
FOR IMMEDIATE RELEASE
Pharmaxis Selects Medidata Solutions to Increase Efficiency of
Clinical Data Management and Reporting
Global Specialty Pharmaceutical Company Chooses Medidata Rave®
After Eight-Vendor Selection Process
NEW YORK, NY – October 30, 2006 – Medidata Solutions, a global provider of electronic clinical data capture, management and reporting solutions, today announced that Pharmaxis Ltd is implementing Medidata Rave as its platform to conduct future clinical trials in the therapeutic areas of respiratory and autoimmune diseases. Medidata Rave was chosen by Pharmaxis from a group of eight vendors as the system to manage its Phase II–III clinical trials throughout Australia, the United States and the United Kingdom.
Based in Sydney, Pharmaxis is a global specialty pharmaceutical company involved in the research, development and marketing of human therapeutic products for chronic respiratory and autoimmune diseases. Pharmaxis had previously outsourced their clinical trial data management, but in early 2006 decided to bring a system in-house.
Pharmaxis focused on finding a solution that was user-friendly for sites and offered broad functionality for data managers, easy access to reports for monitors and a sound security model. After the initial review of eight EDC vendors, Pharmaxis narrowed the pool over a period of three months. Impressed with Medidata Rave’s intuitive technology design and ability to meet the needs of the entire clinical study team, Pharmaxis intends to standardize on Rave after initial validation is completed.
“Medidata Rave is a modern technology that has the look, feel and features of a system that was designed from the ground up with all users in mind, from study coordinators to data managers, and from sites to sponsors,” said Tim Bower, data management coordinator at Pharmaxis. “As a web-based, browser-independent, thin-client system, Rave is easily accessible anywhere in the world where an Internet connection is available. Also critical to our selection of Rave was its flexibility to match our processes and grow with us over time, offering the opportunity to integrate with other technologies should the need arise.”
With Rave’s intuitive interface, with fast and simple navigation, Pharmaxis anticipates that Rave will save time and provide easier access to reports, ultimately resulting in a smoother close-out of studies.
“The addition of Pharmaxis to our client roster demonstrates our continued momentum and expansion into global markets,” said Tarek Sherif, CEO of Medidata Solutions. “An innovative specialty pharma, Pharmaxis has recognized how an extensible, enterprisewide clinical data management solution will streamline its process for driving products to market. We look forward to working with Pharmaxis to achieve its goal of standardizing on Medidata Rave.”
About Pharmaxis Ltd
Pharmaxis Ltd (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and autoimmune diseases. The company’s development pipeline of products includes Aridol™ for the management of asthma, Bronchitol™ for cystic fibrosis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis.
Pharmaxis was listed on the Australian Stock Exchange in November 2003 (symbol PXS), and on NASDAQ (symbol PXSL) in August 2005. For more information about Pharmaxis, go to www.pharmaxis.com.au.
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data—the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing lifeenhancing treatments to market—on five continents and in more than 70 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com